Comparative Pharmacology
Head-to-head clinical analysis: GLYCOPYRRONIUM TOSYLATE versus TROPICAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCOPYRRONIUM TOSYLATE versus TROPICAMIDE.
GLYCOPYRRONIUM TOSYLATE vs TROPICAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), inhibiting parasympathetic nerve impulses. Blocks the action of acetylcholine at autonomic effector sites innervated by postganglionic cholinergic nerves, reducing salivary, bronchial, and gastric secretions, and relaxing smooth muscle.
Antimuscarinic agent that blocks acetylcholine at muscarinic receptors in the ciliary muscle and sphincter muscle of the iris, resulting in mydriasis and cycloplegia.
Glycopyrronium tosylate: 1-2 mg orally 2-3 times daily; maximum 8 mg daily.
1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated in 5 minutes if needed for maximal effect; for cycloplegic refraction, 1-2 drops of 1% solution repeated in 5 minutes.
None Documented
None Documented
Clinical Note
moderateTropicamide + Fesoterodine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine."
Clinical Note
moderateTropicamide + Quinidine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine."
Clinical Note
moderateTropicamide + Darifenacin
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Darifenacin."
Clinical Note
moderateTropicamide + Topiramate
Terminal elimination half-life: 0.6–1.2 hours in adults with normal renal function; prolonged in renal impairment (up to 3–4 hours). Clinically, duration of action is longer than half-life due to high receptor affinity.
Terminal elimination half-life is approximately 2 hours; clinically, mydriasis and cycloplegia persist for 4-8 hours despite rapid plasma clearance.
Renal: 85% unchanged; biliary/fecal: ~5% as metabolites and unchanged drug; elimination primarily via glomerular filtration and tubular secretion.
Primarily renal excretion of unchanged drug and metabolites; approximately 30% unchanged in urine within 6 hours; minor biliary/fecal elimination (<5%).
Category C
Category A/B
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Topiramate."